

Grace Lai-Hung Wong

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3766779/grace-lai-hung-wong-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

375 papers	18,327 citations	75 h-index	124 g-index
422 ext. papers	22,883 ext. citations	6.4 avg, IF	6.84 L-index

#	Paper	IF	Citations
375	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 51, 454-62	11.2	790
374	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut</i> , 2010 , 59, 969-74	19.2	431
373	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017 , 66, 1022-1030	13.4	415
372	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E1317-25	11.5	392
371	Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1660-5	2.2	336
370	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , 2012 , 61, 409-15	19.2	328
369	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. <i>Hepatology</i> , 2013 , 58, 1537-47	11.2	321
368	Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. <i>Gut</i> , 2021 , 70, 698-706	19.2	312
367	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 36-44 ^{3.4}		307
366	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , 2016 , 65, 1359-68	19.2	271
365	Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 1462-8	6.9	271
364	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 254-69	6.1	249
363	Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1862-71	0.7	244
362	High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 177-82	2.2	242
361	Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. <i>Lancet, The</i> , 2007 , 369, 1621-6	40	239
360	Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. <i>Radiology</i> , 2013 , 269, 910-8	20.5	218
359	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 70-85	4	211

358	Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 461-478	24.2	206
357	Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. <i>PLoS ONE</i> , 2013 , 8, e62885	3.7	205
356	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2011 , 60, 1721-7	19.2	205
355	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. <i>Hepatology</i> , 2010 , 52, 1232-41	11.2	192
354	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <i>Annals of Hepatology</i> , 2013 , 12, 256-262	3.1	187
353	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. <i>Journal of Hepatology</i> , 2012 , 56, 833-9	13.4	184
352	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. <i>Journal of Hepatology</i> , 2013 , 59, 536-42	13.4	183
351	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. <i>Gut</i> , 2011 , 60, 829-36	19.2	183
350	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2014 , 60, 339-45	13.4	173
349	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. <i>International Journal of Cancer</i> , 2009 , 124, 2766-70	7.5	171
348	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. <i>Gut</i> , 2009 , 58, 111-7	19.2	168
347	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1306-14; quiz 1315	0.7	164
346	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4138-48	3.1	162
345	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. <i>Journal of Hepatology</i> , 2012 , 56, 1363-70	13.4	162
344	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. <i>Hepatology</i> , 2017 , 65, 54-64	11.2	160
343	Bacterial microbiota profiling in gastritis without <i>Helicobacter pylori</i> infection or non-steroidal anti-inflammatory drug use. <i>PLoS ONE</i> , 2009 , 4, e7985	3.7	155
342	International incidence and mortality trends of liver cancer: a global profile. <i>Scientific Reports</i> , 2017 , 7, 45846	4.9	152
341	Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 1154-61	6.9	152

340	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , 2012 , 56, 533-40	15.4	151
339	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015 , 64, 667-72	19.2	148
338	Long-term follow-up of patients with obscure gastrointestinal bleeding after negative capsule endoscopy. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1224-8	0.7	145
337	Fatty pancreas, insulin resistance, and β -cell function: a population study using fat-water magnetic resonance imaging. <i>American Journal of Gastroenterology</i> , 2014 , 109, 589-97	0.7	140
336	Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. <i>Gastroenterology</i> , 2013 , 144, 933-44	13.3	136
335	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017 , 65, 1145-1155	11.2	135
334	Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. <i>Gastroenterology</i> , 2012 , 142, 513-520.e1	13.3	134
333	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 1104-12	6.1	134
332	Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1027-35	6.9	127
331	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , 2011 , 54, 236-42	13.4	110
330	Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 300-5	4	109
329	Efficacy of cap-assisted colonoscopy in comparison with regular colonoscopy: a randomized controlled trial. <i>American Journal of Gastroenterology</i> , 2009 , 104, 41-6	0.7	106
328	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 848-55	4	106
327	Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , 2015 , 62, 182-9	13.4	104
326	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 56-67	18.8	103
325	High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. <i>Gastroenterology</i> , 2009 , 137, 525-31	13.3	99
324	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. <i>Hepatology</i> , 2014 , 59, 986-95	11.2	98
323	PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 139-46	4	98

322	Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 1095-103	6.1	97
321	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018 , 69, 1349-1356	13.4	96
320	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 617-627	6.1	94
319	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020 , 158, 215-225.e6	13.3	94
318	Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. <i>Liver International</i> , 2008 , 28, 79-87	7.9	93
317	Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. <i>Journal of Infectious Diseases</i> , 2011 , 204, 408-14	7	91
316	Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1323-31	6.1	89
315	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 667-676	4	87
314	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 29, 387-96	6.1	87
313	Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. <i>Antiviral Therapy</i> , 2011 , 16, 1249-57	1.6	86
312	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 1002-7	4	85
311	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010 , 51, 1945-53	11.2	85
310	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2017 , 67, 902-908	13.4	84
309	Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. <i>Clinical Microbiology Reviews</i> , 2020 , 33,	34	82
308	PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 532-9	6.1	82
307	Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1682-8	0.7	82
306	Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes. <i>Annals of Surgery</i> , 2013 , 257, 922-8	7.8	81
305	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017 , 67, 577-584	13.4	80

304	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1215-22	6.1	80
303	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2019 , 70, 361-370	13.4	80
302	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 883-93	6.1	79
301	On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2011 , 16, 165-72	1.6	75
300	Histone Deacetylase HDAC8 Promotes Insulin Resistance and β -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015 , 75, 4803-16	10.1	74
299	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 447-456	6.1	73
298	Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. <i>American Journal of Gastroenterology</i> , 2008 , 103, 3071-81	0.7	73
297	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 86-98 ⁴		71
296	Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. <i>Journal of Hepatology</i> , 2018 , 69, 278-285	13.4	70
295	Update of liver fibrosis and steatosis with transient elastography (Fibroscan). <i>Gastroenterology Report</i> , 2013 , 1, 19-26	3.3	70
294	New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1391-6	4	69
293	Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 1361-6	6.9	69
292	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , 2016 , 63, 754-63	11.2	68
291	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019 , 68, 2057-2064	19.2	65
290	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , 2021 , 70, 733-742	19.2	65
289	Transient elastography: Kill two birds with one stone?. <i>World Journal of Hepatology</i> , 2013 , 5, 264-74	3.4	64
288	Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. <i>Disease Markers</i> , 2015 , 2015, 564057	3.2	62
287	Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 517-26	6.1	61

286	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. <i>Hepatology</i> , 2015 , 62, 684-93	11.2	60
285	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , 2015 , 63, 1190-7	13.4	59
284	Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 227-33	6.9	59
283	Changes in Crohn's disease phenotype over time in the Chinese population: validation of the Montreal classification system. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 536-41	4.5	57
282	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , 2014 , 61, 708-9	13.4	56
281	Inter-observer variations on interpretation of capsule endoscopies. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 283-6	2.2	56
280	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , 2015 , 10, e0139310	3.7	56
279	Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 914-21	4	53
278	Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. <i>Lancet, The</i> , 2017 , 389, 2375-2382	4.0	52
277	Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. <i>United European Gastroenterology Journal</i> , 2017 , 5, 76-85	5.3	51
276	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019 , 71, 1141-1151	13.4	51
275	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 776-787	18.8	51
274	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1812-1823	0.7	49
273	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2017 ,	13.4	49
272	Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 1057-66	6.1	49
271	Association between anthropometric parameters and measurements of liver stiffness by transient elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 295-302.e1-3	6.9	48
270	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2017 ,	13.4	47
269	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , 2018 , 64, 1239-1249	5.5	47

268	Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 197-208	6.1	47
267	Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. <i>American Journal of Gastroenterology</i> , 2010 , 105, 132-8	0.7	47
266	Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. <i>Liver Transplantation</i> , 2007 , 13, 1228-35	4.5	47
265	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. <i>Journal of Hepatology</i> , 2015 , 62, 807-15	13.4	46
264	Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 304-12	6.7	46
263	Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 731-40	6.1	46
262	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020 , 115, 271-280	0.7	45
261	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018 , 69, 793-802	13.4	45
260	Surrogate end points and long-term outcome in patients with chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 1113-20	6.9	44
259	Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 730-737	6.1	42
258	Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1326-35	6.1	42
257	Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 783-90.e1	6.9	42
256	An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. <i>Nature Communications</i> , 2018 , 9, 5214	17.4	42
255	Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 199-208	6.1	41
254	Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage. <i>Gastroenterology</i> , 2016 , 151, 271-7	13.3	41
253	Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 175-182	6.1	40
252	Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1059-68	6.1	39
251	Repeat-screening colonoscopy 5 years after normal baseline-screening colonoscopy in average-risk Chinese: a prospective study. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2028-34	0.7	39

250	Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 1001-1010	6.1	37
249	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 984-992	6.1	37
248	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010 , 15, 145-55	1.6	37
247	Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 891-8	6.1	37
246	Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. <i>Liver International</i> , 2018 , 38, 503-514	7.9	36
245	Liver injury is common among chronic abusers of ketamine. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1759-62.e1	6.9	36
244	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2161-2171.e5	6.9	36
243	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 185-198	18.8	36
242	Liver fibrosis and fatty liver in Asian HIV-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 411-21	6.1	35
241	Prediction of fibrosis progression in chronic viral hepatitis. <i>Clinical and Molecular Hepatology</i> , 2014 , 20, 228-36	6.9	35
240	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1363-1369	4	34
239	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 128-141	6.9	34
238	Current developments in nucleoside/nucleotide analogues for hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 607-22	4.2	33
237	One-stop clinic for ketamine-associated uropathy: report on service delivery model, patientsR characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. <i>BJU International</i> , 2014 , 114, 754-60	5.6	33
236	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020 , 40, 581-589	7.9	33
235	Unmet need in chronic hepatitis B management. <i>Clinical and Molecular Hepatology</i> , 2019 , 25, 172-180	6.9	32
234	Modelling NAFLD disease burden in four Asian regions-2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 801-811	6.1	31
233	Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6515-22	5.6	31

232	Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 1124-9	6.9	30
231	Predictors of treatment response in chronic hepatitis B. <i>Drugs</i> , 2009 , 69, 2167-77	12.1	30
230	Initial experience of real-time capsule endoscopy in monitoring progress of the videocapsule through the upper GI tract. <i>Gastrointestinal Endoscopy</i> , 2007 , 66, 1211-4	5.2	30
229	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 765-773.e2	6.9	29
228	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 825-34	3.4	29
227	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1842-8	4	29
226	Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. <i>Clinical and Molecular Hepatology</i> , 2018 , 24, 108-113	6.9	29
225	HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1111-1119	0.7	28
224	Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 989-1000	6.1	28
223	Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 802-13	6.1	28
222	Personalized management of cirrhosis by non-invasive tests of liver fibrosis. <i>Clinical and Molecular Hepatology</i> , 2015 , 21, 200-11	6.9	28
221	Targeted hepatitis C screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 116-20	4	28
220	A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2205-11	0.7	28
219	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009 , 14, 489-499	1.6	28
218	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1278-1284	11.6	27
217	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1037-1048	6.1	27
216	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. <i>Liver International</i> , 2011 , 31, 1047-53	7.9	27
215	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019 , 114, 916-928	0.7	27

214	Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1787-1794	4	26
213	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 506-514	4	26
212	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 72, 847-854	13.4	26
211	Long-Term follow-up of Lamivudine Treatment in Patients with Severe Acute Exacerbation of Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2008 , 13, 571-579	1.6	26
210	Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. <i>Journal of Hepatology</i> , 2014 , 60, 809-15	13.4	25
209	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. <i>Journal of Digestive Diseases</i> , 2016 , 17, 538-546	3.3	25
208	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , 2020 , 72, 57-66	13.4	25
207	Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 912-918	6.1	24
206	Current Knowledge of Occult Hepatitis B Infection and Clinical Implications. <i>Seminars in Liver Disease</i> , 2019 , 39, 249-260	7.3	23
205	A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: A randomized trial. <i>Liver International</i> , 2018 , 38, 636-644	7.9	23
204	Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1022-6	6.9	23
203	Long-Term Lamivudine Treatment is Associated with a Good Maintained Response in Severe Acute Exacerbation of Chronic Hbeag-Negative Hepatitis B. <i>Antiviral Therapy</i> , 2006 , 11, 465-471	1.6	23
202	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019 , 13, 587-598	8.8	22
201	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 484-491	4	22
200	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 241-248	4	22
199	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020 , 221, 389-399	7	22
198	Virological Response to Different Combination Regimes of Peginterferon α 2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007 , 12, 815-823	1.6	22
197	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1453-1460.e1	6.9	20

196	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , 2020 , 72, 1230-1241	11.2	20
195	Treatment of non-alcoholic steatohepatitis with <i>Phyllanthus urinaria</i> : a randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 57-62	4	19
194	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1762-9	4	19
193	Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. <i>Neurogastroenterology and Motility</i> , 2011 , 23, 155-60, e31	4	19
192	Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 63-9	4	19
191	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. <i>Hepatology</i> , 2016 , 64, 1507-1517	11.2	19
190	Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 145-53	6.1	19
189	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <i>Hepatology</i> , 2020 , 71, 444-455	11.2	19
188	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 136-145.e6	6.9	19
187	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. <i>Hepatology</i> , 2019 , 70, 971-981	11.2	18
186	Non-invasive assessments for liver fibrosis: The crystal ball we long for. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1009-1015	4	18
185	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , 2014 , 65, 174-86	7.3	18
184	Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 1830-6	9.7	18
183	Higher estimated net endogenous Acid production may be associated with increased prevalence of nonalcoholic Fatty liver disease in chinese adults in Hong Kong. <i>PLoS ONE</i> , 2015 , 10, e0122406	3.7	18
182	Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1213-1224	6.1	17
181	Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 6006-12	5.6	17
180	Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 3541-7	4	17
179	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1629-1638	0.7	17

178	Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. <i>Nucleic Acids Research</i> , 2018 , 46, 8832-8847	20.1	16
177	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2332-8	5.1	16
176	Lamivudine monophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. <i>Journal of Medical Virology</i> , 2009 , 81, 224-9	19.7	16
175	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020 , 9, 167-181	9.1	16
174	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016 , 69, 971-984	7.3	15
173	Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe. <i>Annals of Hepatology</i> , 2013 , 12, 402-412	3.1	15
172	Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. <i>Liver International</i> , 2019 , 39, 271-279	7.9	15
171	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 347-352	3	15
170	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1230-1233	4	14
169	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , 2012 , 32, 271-8	7.9	14
168	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 972-81	6.1	14
167	Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 543-550	4	14
166	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009 , 14, 489-99	1.6	14
165	Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection. <i>Clinical Infectious Diseases</i> , 2020 , 70, 660-666	11.6	13
164	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020 , 50, 1024-1031	5.1	13
163	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020 , 115, 867-875	0.7	13
162	Eliminating hepatitis B virus as a global health threat. <i>Lancet Infectious Diseases, The</i> , 2016 , 16, 1313-1314	45.5	13
161	Health-related quality of life in Chinese patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 592-8	4	13

160	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong-A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021 , 72, e466-e475	11.6	13
159	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , 2021 , 74, 1750-1765	11.2	12
158	Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 126-135	3.4	12
157	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020 , 69, 1116-1126	19.2	12
156	Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon α (40 kDa; PEGASYS®). <i>Antiviral Therapy</i> , 2008 , 13, 555-562	1.6	12
155	Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 716-26	6.1	11
154	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020 , 40, 2719-2731	7.9	11
153	Virus and Host Testing to Manage Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2016 , 62 Suppl 4, S298-S305	11.3	11
152	Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 582-90	4	10
151	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020 , 14, 1023-1033	8.8	10
150	Liver stiffness measurement: simplicity is prerequisite for reliability. <i>Gastroenterology</i> , 2013 , 144, 243-4	13.3	10
149	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues. <i>Antiviral Therapy</i> , 2013 , 18, 979-86	1.6	10
148	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021 , 116, 984-993	0.7	10
147	Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound. <i>World Journal of Radiology</i> , 2009 , 1, 25-36	2.9	10
146	DATA-GRU: Dual-Attention Time-Aware Gated Recurrent Unit for Irregular Multivariate Time Series. <i>Proceedings of the AAAI Conference on Artificial Intelligence</i> , 2020 , 34, 930-937	5	10
145	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. <i>Ultrasound in Medicine and Biology</i> , 2021 , 47, 2803-2820	3.5	10
144	Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. <i>Antiviral Therapy</i> , 2008 , 13, 571-9	1.6	10
143	Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 2210-2219	4	8

142	Efficient Shapelet Discovery for Time Series Classification. <i>IEEE Transactions on Knowledge and Data Engineering</i> , 2020 , 1-1	4.2	8
141	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , 2018 , 38, 1911-1919	7.9	8
140	Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. <i>Antiviral Therapy</i> , 2013 , 18, 671-9	1.6	8
139	Advances in the diagnosis and treatment of liver fibrosis. <i>Hepatoma Research</i> , 2017 , 3, 156	4.3	8
138	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2843-2845.e2	6.9	8
137	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1950-1958.e7	6.9	8
136	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020 , 2, 100152	10.3	8
135	Gastroduodenal Involvement in Asymptomatic Crohn's Disease Patients in Two Areas of Emerging Disease: Asia and Eastern Europe. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 1401-1406	1.5	8
134	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	8
133	Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. <i>Antiviral Therapy</i> , 2007 , 12, 815-23	1.6	8
132	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1641-1647	4	7
131	LBO-03-Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019 , 70, e128	13.4	7
130	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1509-1517	6.1	7
129	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1969-1979	11.6	7
128	Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1190-9	6.1	7
127	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , 2020 , 55, 899-908	6.9	7
126	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory-wide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 934-941	4	7
125	Collateral Effect of Coronavirus Disease 2019 Pandemic on Hospitalizations and Clinical Outcomes in Gastrointestinal and Liver Diseases: A Territory-wide Observational Study in Hong Kong. <i>Gastroenterology</i> , 2020 , 159, 1979-1981.e3	13.3	7

124	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , 2021 , 73, 2238-2250	11.2	7
123	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1274-1283	0.7	7
122	Risks of post-colonoscopy polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis. <i>Gut</i> , 2022 , 71, 100-110	19.2	7
121	Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. <i>Antiviral Therapy</i> , 2006 , 11, 465-71	1.6	7
120	Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 377-385.e5	6.9	6
119	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , 2020 , 5, 1129-1138	4.1	6
118	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 904-914	3.4	6
117	Antiviral drug resistance testing in patients with chronic hepatitis B. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 221-31	4	6
116	Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1040-8	4	6
115	Molecular virology in chronic hepatitis B: genotypes. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005 , 66, 13-6	0.8	6
114	Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. <i>BMJ Open</i> , 2021 , 11, e052310	3	6
113	Asian perspective on NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2021 ,	13.4	6
112	The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. <i>Liver International</i> , 2020 , 40, 549-557	7.9	6
111	Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 470-480	6.1	6
110	Continuous Positive Airway Pressure Does Not Improve Nonalcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea. A Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 493-501	10.2	6
109	Differential Impacts of Multimorbidity on COVID-19 Severity across the Socioeconomic Ladder in Hong Kong: A Syndemic Perspective. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	6
108	How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?. <i>Journal of Hepatology</i> , 2022 , 76, 1249-1262	13.4	6
107	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1071-1078	4	5

106	Is obeticholic Acid the solution to nonalcoholic steatohepatitis?. <i>Gastroenterology</i> , 2015 , 148, 851-2	13.3	5
105	A LEAN treatment for non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2016 , 387, 628-630	4.0	5
104	Cerebellum vasculopathy and normal tension glaucoma in systemic lupus erythematosus: report of a case and review of the literature. <i>Rheumatology International</i> , 2006 , 27, 101-2	3.6	5
103	ACE inhibitors prevent liver-related events in non-alcoholic fatty liver disease.. <i>Hepatology</i> , 2021 ,	11.2	5
102	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 321-331	6.1	5
101	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. <i>Cancer Medicine</i> , 2020 , 9, 7052-7061	4.8	5
100	Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. <i>Gut</i> , 2020 , 69, 652-657	19.2	5
99	Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population.. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	5
98	Quantitative Subtyping of Hepatitis B Virus Reveals Complex Dynamics of Ymdd Motif Mutants Development during Long-Term Lamivudine Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 1041-1050	1.6	5
97	SAT-288-Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019 , 70, e763-e764	13.4	4
96	Huge adrenal hemangioma: a rare cause of deceptively high liver stiffness measurement by transient elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, e37-8	6.9	4
95	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , 2020 , 20, 128	3	4
94	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , 2011 , 55, 497; author reply 498	13.4	4
93	UA-CRNN: Uncertainty-Aware Convolutional Recurrent Neural Network for Mortality Risk Prediction 2019 ,		4
92	Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. <i>BMJ Open</i> , 2021 , 11, e052310	3	4
91	Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. <i>World Journal of Hepatology</i> , 2015 , 7, 2133-5	3.4	4
90	Association of genetic variations with NAFLD in lean individuals. <i>Liver International</i> , 2021 ,	7.9	4
89	Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?. <i>Journal of Gastroenterology</i> , 2020 , 55, 1023-1036	6.9	4

88	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1890-1899	7	4
87	Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. <i>BMC Gastroenterology</i> , 2016 , 16, 100	3	4
86	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021 , 15, 71-81	8.8	4
85	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00300	4.2	4
84	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00324	4.2	4
83	Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS). <i>Antiviral Therapy</i> , 2008 , 13, 555-62	1.6	4
82	Prolonged esophageal transit during wireless capsule endoscopy: a series of five cases and analysis of risk factors. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 176	3	3
81	A Hybrid Residual Network and Long Short-Term Memory Method for Peptic Ulcer Bleeding Mortality Prediction 2018 , 2018, 998-1007	0.7	3
80	How many deaths are caused by non-alcoholic fatty liver disease in the Asia-Pacific region?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 103-105	18.8	3
79	Explainable Uncertainty-Aware Convolutional Recurrent Neural Network for Irregular Medical Time Series. <i>IEEE Transactions on Neural Networks and Learning Systems</i> , 2021 , 32, 4665-4679	10.3	3
78	Implications of COVID-19 for patients with pre-existing digestive diseases: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 258-260	18.8	3
77	Hepatitis B-management of acute infection and active inflammation in pregnancy-a hepatologist's perspective. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020 , 68, 54-65	4.6	3
76	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 2202-2209	4	3
75	Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. <i>Journal of Hepatology</i> , 2021 ,	13.4	3
74	Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
73	Importance-aware personalized learning for early risk prediction using static and dynamic health data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021 , 28, 713-726	8.6	3
72	Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2021 , 19, 329-337	2.5	3
71	Towards finite oral antiviral treatment for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 260-262	18.8	2

70	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1610-1618	4	2
69	Commentary: coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B - authorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1236-7	6.1	2
68	Use of quantitative hepatitis B surface antigen with hepatitis B virus DNA in clinical practice. <i>Clinical Liver Disease</i> , 2013 , 2, 8-10	2.2	2
67	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2021 ,	6.9	2
66	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2021 , 16, 48	8.8	2
65	Reply. <i>Gastroenterology</i> , 2020 , 158, 2312-2313	13.3	2
64	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021 , 11, 5416	4.9	2
63	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab205	1	2
62	Questionnaire survey on knowledge, attitudes, and behaviour towards viral hepatitis among the Hong Kong public. <i>Hong Kong Medical Journal</i> , 2021 ,	0.7	2
61	Macromolecular proton fraction mapping based on spin-lock magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2020 , 84, 3157-3171	4.4	1
60	Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar. <i>PLoS ONE</i> , 2017 , 12, e0181603	3.7	1
59	Is antiviral drug-induced hepatitis B surface antigen loss durable?. <i>Gastroenterology</i> , 2014 , 147, 1435-6	13.3	1
58	Tertiary Prevention of HBV-related HCC in Asia. <i>Current Hepatitis Reports</i> , 2013 , 12, 157-164		1
57	How long will it take to eliminate HCC risk in patients with chronic hepatitis B patients with potent antivirals?. <i>AME Medical Journal</i> , 2017 , 2, 141-141	1	1
56	Reply: To PMID 24519364. <i>Hepatology</i> , 2014 , 60, 1797-8	11.2	1
55	Commentary: predicting survival in hepatocellular carcinoma patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 680; discussion 681	6.1	1
54	Non-invasive algorithms for liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 310-1; discussion 311-3	6.1	1
53	Medical therapy for primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1135-6; discussion 1136-7	6.1	1

52	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis.. <i>JHEP Reports</i> , 2022 , 4, 100441	10.3	1
51	Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 554-561	6.9	1
50	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020 , 92, 1206-1213	19.7	1
49	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , 2021 , 5, 1212-1223	6	1
48	Neurological diseases and risk of mortality in patients with COVID-19 and SARS: a territory-wide study in Hong Kong. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1356-1358	5.5	1
47	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
46	Reply. <i>Hepatology</i> , 2016 , 64, 685-6	11.2	1
45	Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. <i>Liver International</i> , 2019 , 39, 494-502	7.9	1
44	Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues". <i>Journal of Hepatology</i> , 2019 , 70, 796-797	13.4	1
43	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021 , 84, 68-73	3.9	1
42	Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease.. <i>Journal of Clinical and Translational Hepatology</i> , 2021 , 9, 972-982	5.2	1
41	Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy. <i>Antiviral Therapy</i> , 2006 , 11, 1041-9	1.6	1
40	Management of hepatitis B virus reactivation due to treatment of COVID-19.. <i>Hepatology International</i> , 2022 , 16, 257	8.8	1
39	Stopping 5-Aminosalicylic Acid in Ulcerative Colitis Patients in Corticosteroid-free remission is not associated with Increased Risk of Flare: A Territory-wide population-based cohort study.. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022 ,	4	1
38	Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.. <i>World Journal of Gastroenterology</i> , 2022 , 28, 1563-1573	5.6	1
37	Temporal matrix completion with locally linear latent factors for medical applications. <i>Artificial Intelligence in Medicine</i> , 2020 , 107, 101883	7.4	0
36	Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B Infection. <i>Current Hepatology Reports</i> , 2017 , 16, 97-104	1	0
35	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 , 55, 616-617	6.1	0

34	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD.. <i>Metabolism: Clinical and Experimental</i> , 2021 , 128, 154958	12.7	o
33	HCV elimination in Hong Kong - Non-government organisation (NGO) activities. <i>Global Health & Medicine</i> , 2021 , 3, 283-287	2.4	o
32	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 499-509	6.9	o
31	Reply. <i>Hepatology</i> , 2017 , 65, 1780	11.2	
30	Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page". <i>Journal of Hepatology</i> , 2020 , 73, 729-730	13.4	
29	Assessment of HCC Risk in Patients with Chronic HBV (REACH, PAGE-B, and Beyond). <i>Current Hepatology Reports</i> , 2020 , 19, 285-292	1	
28	Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 315-316	6.1	
27	Reply to Boglione et al. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1584-1585	11.6	
26	Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance". <i>Journal of Hepatology</i> , 2017 ,	13.4	
25	Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy? AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 910	6.1	
24	FRI-192-Tenofovir disoproxil fumarate treatment in chronic hepatitis B patients with cirrhosis reduces hepatic decompensation, hepatocellular carcinoma and death. <i>Journal of Hepatology</i> , 2019 , 70, e475	13.4	
23	Commentary: time to update the ALT cut-off?. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 682-681	3.1	
22	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , 2010 , 59, 277.1-277	19.2	
21	PWE-293 Low glycaemic index dietary intervention for patients with non-alcoholic fatty liver disease in the general populationA randomised controlled trial. <i>Gut</i> , 2012 , 61, A417.1-A417	19.2	
20	Anasarca secondary to problems in three organs: one man with three diseases?. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 1651-3	4.3	
19	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. <i>GastroHep</i> , 2022 , 2022, 1-13	1	
18	Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 508-508	2.2	
17	Prediction of HCC Using Liver Stiffness Measurements 2020 , 375-382		

16	Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC. <i>AIMS Medical Science</i> , 2016 , 3, 162-178	0.4
15	Reply. <i>Hepatology</i> , 2020 , 71, 1134	11.2
14	Reply to Hoffmann and Wolf. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1782-e1783	11.6
13	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2684-2685	6.9
12	Reply. <i>Hepatology</i> , 2016 , 64, 1820-1821	11.2
11	Letter: factors determining liver fibrosis - more to come. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 171-2	6.1
10	Reply to Sun et al. <i>Clinical Infectious Diseases</i> , 2020 , 70, 2748-2749	11.6
9	Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 87	18.8
8	Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong.. <i>Kidney360</i> , 2021 , 2, 721-728	1.8
7	Letter: chronic kidney disease risk in patients with chronic hepatitis B-authorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1324	6.1
6	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , 2021 , 3, 261-269	1
5	Reply to Letters to the Editor: Clinical outcomes in COVID-19 patients with current or past hepatitis B virus infection. <i>Hepatology</i> , 2021 ,	11.2
4	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , 2021 , 4, e352	2.2
3	Targeting an energy sensor to prevent energy excess in the liver. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 876-877	18.8
2	Chronic hepatitis B and D 2022 , 447-455	
1	Reply.. <i>Hepatology</i> , 2022 ,	11.2